Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications

Journal of Clinical Oncology

Volumn 13, Issue 5, 1995, Pages 1195-1200

  Ghossein, Ronald A ^b   Scher, Howard I ^b   Gerald, William L ^b   Kelly, W K ^b   Curley, Tracy ^b   Amsterdam, Alison ^b   Zhang, Zuo Feng ^b   Rosai, Juan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER STAGING; CANCER SURVIVAL; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0029033526     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1995.13.5.1195     Document Type: Article

References (30)

1. Boring CC, Squires TS, Tong T, et al: Cancer statistics, 1994. Ca 44:7-26, 1994
2. Partin AW, Yoo J, Carter HB, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993
3. Kleer E, Larson-Keller JJ, Zincke H, et al: Ability of preoperative serum prostate-specific antigen value to predict pathological stage and DNA ploidy: Influence of clinical stage and tumor grade. Urology 41:207-216, 1993
4. van den Ouden D, Davidson PJT, Hop W, et al: Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol 151:646-651, 1994
5. Leibel SA, Zelefsky MJ, Kutcher GJ, et al: The biological basis and clinical application of three-dimensional conformal external beam radiation therapy in carcinoma of the prostate. Semin Oncol 21:580-597, 1994
6. Miller JI, Ahmann FR, Drach GW, et al: Clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol 147:956-961, 1992
7. Moreno JG, Croce CM, Fischer R, et al: Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52:6110-6112, 1992
8. Katz AE, Olsson CA, Raffo AJ, et al: Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urol 43:765-775, 1994
9. Leo ME, Bilhartz DL, Bergstralh EJ, et al: Prostate specific antigen in hormonally treated stage D2 prostate cancer: Is it always an accurate indicator of disease status? J Urol 145:802-806, 1991
10. Pienta KJ, Coffey DS: Cell motility as a chemotherapeutic target, in Isaacs JT (ed): Prostate Cancer. Cold Spring Harbor, NY, Cold Spring Harbor Press, 1991, pp 255-263
11. Yamaoka M, Yamamoto T, Ikeyama S, et al: Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 53:5233-5236, 1993
12. Qui SD, Young CY, Bilhartz DL, et al: In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144:1550-1556, 1990
13. Schroeder FF, Hermanek P, Denis L, et al: The TNM classification of prostatic carcinoma. Prostate 4:129-138, 1992 (suppl)
14. Ben-Ezra J, Johnson J, Rossi J, et al: Effect of fixation on the amplification of nucleic acids from paraffin-embedded material by the polymerase chain reaction. J Histochem Cytochem 34:351-354, 1991
15. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977
16. Mehta CR, Patel NR: A network algorithm for performing Fischer's exact test in r X c contingency tables. J Am Stat Assoc 78:427-434, 1983
17. Landis RJ, Hetman ER, Koch GG: Average partial association in three-way contingency tables: A review and discussion of alternative tests. Int Stat Rev 46:237-254, 1986
18. SAS/STAT User Guide, version 6. Cary, NC, SAS Institute Inc, 1990
19. Doyle GM, Mohler JL: Prediction of metastatic potential of aspirated cells from the Dunning R-3327 prostatic adenocarcinoma model. J Urol 147:756-759, 1992
20. Jacobs SC: Spread of prostatic carcinoma to bone. Urology 21:337-344, 1983
21. Zetter BR: The cellular basis of site-specific tumor metastasis. N Engl J Med 322:605-611, 1990
22. Datta YH, Adams PT, Drobyski WR, et al: Sensitive detection of occult breast cancer by reverse-transcriptase polymerase chain reaction. J Clin Oncol 12:475-482, 1994
23. Mattano LA, Moss TJ, Emerson SG: Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 52:4701-4705, 1992
24. Schellhammer PF, Wright GL: Biomolecular and clinical characteristics of PSA and other candidate prostate tumor markers. Urol Clin North Am 20:597-606, 1993
25. Su SL, Israeli RS, Miller WH, et al: Sensitive detection of prostate hematogenous micrometastases using prostate specific antigen (PSA) and prostate specific membrane antigen (PSM) derived primers in the polymerase chain reaction. Proc Am Assoc Cancer Res 35:1616, 1994 (abstr)
26. Seiden MV, Kantoff PW, Krithivas K, et al: Detection of circulating tumor cells in men with localized or metastatic prostate cancer. J Clin Oncol 12:2634-2639, 1994
27. Smith MR, Biggar S, Hussain M: Nested PCR detects prostate specific antigen RNA in non-prostate cells. Proc Am Assoc Cancer Res 35:197, 1994 (abstr)
28. Oesterling JE: Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907-923, 1991
29. Warembourg M, Tranchant O, Atger M, et al: Uteroglobin messenger ribonucleic acid: Localization in rabbit uterus and lung by in situ hybridization. Endocrinology 119:1632-1640, 1986
30. Israeli R, Powell CT, Corr JG, et al: Expression of the prostate-specific membrane antigen. Cancer Res 54:1807-1811, 1994